帯状疱疹ワクチンの市場規模、シェア、動向分析レポート：製品タイプ別、ワクチンタイプ別、最終用途別、地域別、セグメント予測、2025～2030年

帯状疱疹ワクチン市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の帯状疱疹ワクチンの市場規模は、2025～2030年にかけて15.7%のCAGRを記録し、2030年までに112億6,000万米ドルに達する見込みです。

先進諸国における帯状疱疹の発症率の増加と帯状疱疹に関する高い認知度が市場拡大に寄与しています。CDCによると、米国では毎年100万件近くの帯状疱疹の症例が報告されています。さらに、同国では3人に1人が一生のうちに発症すると言われています。

ワクチンの採用が増加し、さまざまな政府規制機関によるワクチン接種の推奨が増加していることが、予測期間にわたって市場を牽引すると予想されます。例えば、2019年2月、英国の予防接種合同委員会（JCVI）は、60～70歳の成人の帯状疱疹予防に組換えワクチンの使用を推奨しています。

数カ国の国家予防接種プログラムに帯状疱疹ワクチンが含まれることで、ワクチン需要が促進されると予想されます。例えば、英国では2013年から帯状疱疹ワクチンが国家予防接種プログラムの一部となっています。英国は欧州地域で初めて国家予防接種プログラムに帯状疱疹ワクチンを導入した国であり、ワクチン1回分の接種費用は国民保健サービス（NHS）で約130米ドルです。同様に、米国、イタリア、オーストラリア、カナダのいくつかの州、韓国などの他の国も予防接種プログラムにこのワクチンを組み込んでいます。

さらに、病気を発症するリスクのある人々の意識を高めるために市場関係者や規制当局が行っている好ましい取り組みが、今後数年間の市場成長を促進すると予想されます。例えば、GlaxoSmithKline plc.は、予防接種に関連する利点について人々を教育することにより、高齢者の予防接種率を高めるキャンペーンを開始しました。

ワクチンの高い有効性により、予測期間中の普及が期待されます。臨床試験結果によると、シングリックスは帯状疱疹と帯状疱疹後神経痛の予防に非常に有効です。シングリックスの2回投与は、50歳以上の成人において90％以上の予防効果があります。接種後少なくとも4年間は85％以上の予防効果が持続します。

ワクチンが低価格で入手可能であることに加え、先進諸国では罹患率が高く、ワクチン接種率も高いことから、市場の成長に拍車がかかると予想されます。英国、米国、フランス、カナダ、ドイツ、韓国の帯状疱疹に対するワクチン接種率は、他の国に比べて高いです。例えば、英国は帯状疱疹ワクチンの接種率が最も高く、対象となる成人の60%以上が接種を受けています。

帯状疱疹ワクチン市場レポートのハイライト

• 2024年の帯状疱疹ワクチン市場は、シングリックスが94.14%の最大売上シェアを占め、支配的でした。
• 2024年の帯状疱疹ワクチン市場は、民間ヘルスケア機関が68.33%の最大売上シェアを占めました。
• 2024年の帯状疱疹ワクチン市場において、組み換えワクチンが94.14%の収益シェアを占め、最大シェアを占めました。
• 北米の帯状疱疹ワクチン市場は2024年に世界市場をリードし、62.26%の最大収益シェアを占めました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 帯状疱疹ワクチン市場の変数、動向、範囲

• 市場イントロダクション/系統展望
• 市場規模と成長展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 帯状疱疹ワクチン市場の分析ツール
  • ポーター分析
  • PESTEL分析

第4章 帯状疱疹ワクチン市場：製品タイプの推定・動向分析

• セグメントダッシュボード
• 帯状疱疹ワクチン市場：製品タイプ別の変動分析、2024年および2030年
• シングリックス
• ゾスタバックス
• スカイゾスター

第5章 帯状疱疹ワクチン市場：ワクチンタイプの推定・動向分析

• セグメントダッシュボード
• 帯状疱疹ワクチン市場：ワクチンタイプ別の変動分析、2024年および2030年
• 組み換えワクチン
• 生弱毒化ワクチン

第6章 帯状疱疹ワクチン市場：最終用途の推定・動向分析

• セグメントダッシュボード
• 帯状疱疹ワクチン市場：最終用途別の変動分析、2024年および2030年
• 民間ヘルスケア機関
• 政府ヘルスケア機関

第7章 帯状疱疹ワクチン市場：地域の推定・動向分析

• 地域別の市場シェア分析、2024年および2030年
• 市場ダッシュボード
• 市場スナップショット
• 市場規模、予測動向分析、2018～2030年
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業分類
• 企業ヒートマップ分析
• 企業プロファイル
  • GlaxoSmithKline plc.
  • Pfizer Inc.
  • Merck &Co., Inc.
  • CanSinoBIO
  • Vaccitech
  • Green Cross Corp
  • Geneone Life Science
  • SK Bioscience

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Leading Market Players Anticipated to Witness Highest Growth
• Table 4 Global Shingles Vaccines Market, By Region, 2018 - 2030 (USD Million)
• Table 5 Global Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
• Table 6 Global Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
• Table 7 Global Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
• Table 8 North America Shingles Vaccines Market, By Country, 2018 - 2030 (USD Million)
• Table 9 North America Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
• Table 10 North America Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
• Table 11 North America Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
• Table 12 U.S Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
• Table 13 U.S Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
• Table 14 U.S Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
• Table 15 Canada Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
• Table 16 Canada Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
• Table 17 Canada Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
• Table 18 Mexico Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
• Table 19 Mexico Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
• Table 20 Mexico Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
• Table 21 Europe Shingles Vaccines Market, By Country, 2018 - 2030 (USD Million)
• Table 22 Europe Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
• Table 23 Europe Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
• Table 24 Europe Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
• Table 25 UK Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
• Table 26 UK Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
• Table 27 UK Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
• Table 28 Germany Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
• Table 29 Germany Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
• Table 30 Germany Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
• Table 31 France Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
• Table 32 France Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
• Table 33 France Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
• Table 34 Italy Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
• Table 35 Italy Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
• Table 36 Italy Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
• Table 37 Spain Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
• Table 38 Spain Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
• Table 39 Spain Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
• Table 40 Denmark Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
• Table 41 Denmark Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
• Table 42 Denmark Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
• Table 43 Sweden Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
• Table 44 Sweden Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
• Table 45 Sweden Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
• Table 46 Norway Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
• Table 47 Norway Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
• Table 48 Norway Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
• Table 49 Asia Pacific Shingles Vaccines Market, By Country, 2018 - 2030 (USD Million)
• Table 50 Asia Pacific Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
• Table 51 Asia Pacific Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
• Table 52 Asia Pacific Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
• Table 53 Japan Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
• Table 54 Japan Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
• Table 55 Japan Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
• Table 56 China Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
• Table 57 China Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
• Table 58 China Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
• Table 59 India Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
• Table 60 India Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
• Table 61 India Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
• Table 62 South Korea Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
• Table 63 South Korea Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
• Table 64 South Korea Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
• Table 65 Australia Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
• Table 66 Australia Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
• Table 67 Australia Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
• Table 68 Thailand Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
• Table 69 Thailand Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
• Table 70 Thailand Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
• Table 71 Latin America Shingles Vaccines Market, By Country, 2018 - 2030 (USD Million)
• Table 72 Latin America Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
• Table 73 Latin America Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
• Table 74 Latin America Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
• Table 75 Brazil Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
• Table 76 Brazil Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
• Table 77 Brazil Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
• Table 78 Argentina Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
• Table 79 Argentina Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
• Table 80 Argentina Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
• Table 81 Middle East and Africa Shingles Vaccines Market, By Country, 2018 - 2030 (USD Million)
• Table 82 Middle East and Africa Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
• Table 83 Middle East and Africa Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
• Table 84 Middle East & Africa Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
• Table 85 South Africa Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
• Table 86 South Africa Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
• Table 87 South Africa Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
• Table 88 Saudi Arabia Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
• Table 89 Saudi Arabia Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
• Table 90 Saudi Arabia Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
• Table 91 UAE Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
• Table 92 UAE Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
• Table 93 UAE Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
• Table 94 Kuwait Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
• Table 95 Kuwait Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
• Table 96 Kuwait Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Shingles Vaccine market segmentation
• Fig. 2 Data analysis models
• Fig. 3 Market formulation and validation
• Fig. 4 Data validating & publishing
• Fig. 5 Market research process
• Fig. 6 Information procurement
• Fig. 7 Primary research
• Fig. 8 Value-chain-based sizing & forecasting
• Fig. 9 QFD modelling for market share assessment
• Fig. 10 Market formulation & validation
• Fig. 11 Commodity flow analysis
• Fig. 12 Market outlook
• Fig. 13 Segment snapshot-1
• Fig. 14 Segment snapshot-2
• Fig. 15 Competitive landscape snapshot
• Fig. 16 Market trends & outlook
• Fig. 17 Porter's five force analysis
• Fig. 18 PESTEL analysis
• Fig. 19 Shingles Vaccine market: Product outlook key takeaways
• Fig. 20 Shingles Vaccine market: Product movement analysis
• Fig. 21 Shingrix market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 22 Zostavax market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 23 SKYZoster market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 24 Shingles Vaccine market: Vaccine Type outlook key takeaways
• Fig. 25 Shingles Vaccine market: Vaccine Type movement analysis
• Fig. 26 Recombinant vaccine market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 27 Live attenuated vaccine market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 28 Shingles Vaccine market: End Use outlook key takeaways
• Fig. 29 Shingles Vaccine market: End Use movement analysis
• Fig. 30 Private healthcare settings market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 31 Government healthcare settings market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 32 Regional marketplace outlook, 2024 & 2030 (USD million)
• Fig. 33 Regional marketplace: Key takeaways
• Fig. 34 North America shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 35 Key country dynamics
• Fig. 36 U.S. shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 37 Key country dynamics
• Fig. 38 Canada shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 39 Key country dynamics
• Fig. 40 Mexico shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 41 Europe shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 42 Key country dynamics
• Fig. 43 UK shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 44 Key country dynamics
• Fig. 45 Germany shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 46 Key country dynamics
• Fig. 47 France shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 48 Key country dynamics
• Fig. 49 Spain shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 50 Key country dynamics
• Fig. 51 Italy shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 52 Key country dynamics
• Fig. 53 Denmark shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 54 Key country dynamics
• Fig. 55 Sweden shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 56 Key country dynamics
• Fig. 57 Norway shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 58 Asia Pacific shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 59 Key country dynamics
• Fig. 60 Japan shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 61 Key country dynamics
• Fig. 62 China shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 63 Key country dynamics
• Fig. 64 India shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 65 Key country dynamics
• Fig. 66 Australia shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 67 Key country dynamics
• Fig. 68 South Korea shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 69 Key country dynamics
• Fig. 70 Thailand shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 71 Key country dynamics
• Fig. 72 Latin America shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 73 Key country dynamics
• Fig. 74 Brazil shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 75 Key country dynamics
• Fig. 76 Argentina shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 77 Key country dynamics
• Fig. 78 Middle East & Africa shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 79 Key country dynamics
• Fig. 80 South Africa shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 81 Key country dynamics
• Fig. 82 Saudi Arabia shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 83 Key country dynamics
• Fig. 84 UAE shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 85 Key country dynamics
• Fig. 86 Kuwait shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
• Fig. 87 Market participant categorization
• Fig. 88 Shingles vaccine market position analysis, 2024
• Fig. 89 Strategic framework

Shingles Vaccine Market Growth & Trends:

The global shingles vaccine market size is expected to reach USD 11.26 billion by 2030, registering a CAGR of 15.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing incidence of shingles and high awareness regarding shingles in developed countries are contributing to the market growth. According to the CDC, nearly one million cases of shingles are reported each year in the United States. Furthermore, one out of three individuals in the country will develop the disease in their lifetime.

The increasing adoption of vaccines and an increase in the recommendation of vaccination by different government regulatory bodies are expected to drive the market over the forecast period. For instance, in February 2019, the U.K. Joint Committee of Vaccination and Immunization (JCVI) has recommended the use of the recombinant vaccine to prevent shingles in adults aged 60 to 70 years old.

The inclusion of shingles vaccines in national immunization programs of several countries is anticipated to propel the demand for vaccines. For instance, the shingles vaccine is a part of the national immunization program in the U.K. since 2013. The U.K. is the first country in the European region to introduce shingles vaccine in the national immunization program and it costs around USD 130 to the National Health Service (NHS) for each dose of the vaccine. Similarly, other countries such as the U.S., Italy, Australia, and some provinces of Canada and South Korea have also included the vaccine in their immunization program.

Besides, favorable initiatives undertaken by market players and regulatory bodies to increase the awareness among people who are at risk of developing the disease are expected to fuel the market growth over the coming years. For instance, GlaxoSmithKline plc. has launched a campaign to increase vaccination rates among older adults by educating people about the benefits associated with vaccination.

The high efficacy of vaccines is expected to increase the adoption over the forecast period. According to clinical trial results, Shingrix is highly efficient to prevent shingles and postherpetic neuralgia. Two doses of Shingrix are more than 90% effective to prevent the disease in adults aged 50 years and above. Protection stays above 85% for at least the first four years after getting vaccinated.

The availability of vaccines at lower prices, coupled with a high incidence of the disease and high vaccination rate in developed countries, is anticipated to fuel the market growth. The vaccination rate against shingles in the U.K., the U.S., France, Canada, Germany, and South Korea is higher compared to other countries owing to better reimbursement policies and high awareness levels regarding the disease and vaccines. For instance, the U.K. has the highest shingles vaccine uptake with more than 60% vaccination of eligible adults.

Shingles Vaccine Market Report Highlights:

• The Shingrix segment dominated the shingles vaccine market in 2024, accounting for the largest revenue share of 94.14%.
• The private healthcare settings segment dominated the shingles vaccine market, accounting for the largest revenue share of 68.33% in 2024.
• The recombinant vaccine segment accounted for the largest share of the shingles vaccine market in 2024, comprising a revenue share of 94.14%.
• North America shingles vaccine market led the global market in 2024, holding the largest revenue share of 62.26%

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Shingles Vaccine Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraints Analysis
• 3.4. shingles vaccine Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. Shingles Vaccine Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Shingles Vaccine Market: Product Movement Analysis, 2024 & 2030 (USD Million)
• 4.3. Shingrix
  • 4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Zostavax
  • 4.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. SKYZoster
  • 4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Shingles Vaccine Market: Vaccine Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Shingles Vaccine Market: Vaccine Type Movement Analysis, 2024 & 2030 (USD Million)
• 5.3. Recombinant Vaccine
  • 5.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Live Attenuated Vaccine
  • 5.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Shingles Vaccine Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Shingles Vaccine Market: Type Movement Analysis, 2024 & 2030 (USD Million)
• 6.3. Private Healthcare Settings
  • 6.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Government Healthcare Settings
  • 6.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Shingles Vaccine Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. Mexico
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/ reimbursement structure
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/ reimbursement structure
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework/ reimbursement structure
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/ reimbursement structure
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework/ reimbursement structure
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.2. Argentina
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework/ reimbursement structure
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework/ reimbursement structure
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework/ reimbursement structure
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework/ reimbursement structure
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Heat Map Analysis
• 8.4. Company Profiles
  • 8.4.1. GlaxoSmithKline plc.
    • 8.4.1.1. Participant's Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Recent Developments/ Strategic Initiatives
  • 8.4.2. Pfizer Inc.
    • 8.4.2.1. Participant's Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Recent Developments/ Strategic Initiatives
  • 8.4.3. Merck & Co., Inc.
    • 8.4.3.1. Participant's Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Recent Developments/ Strategic Initiatives
  • 8.4.4. CanSinoBIO
    • 8.4.4.1. Participant's Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Recent Developments/ Strategic Initiatives
  • 8.4.5. Vaccitech
    • 8.4.5.1. Participant's Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Recent Developments/ Strategic Initiatives
  • 8.4.6. Green Cross Corp
    • 8.4.6.1. Participant's Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Recent Developments/ Strategic Initiatives
  • 8.4.7. Geneone Life Science
    • 8.4.7.1. Participant's Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Recent Developments/ Strategic Initiatives
  • 8.4.8. SK Bioscience
    • 8.4.8.1. Participant's Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Recent Developments/ Strategic Initiatives